source
- Bristol Myers Squibb emphasizes pipeline strength and later-stage partnership focus amid patent cliff concernsBristol Myers Squibb used its latest earnings call to outline how it plans to address an upcoming patent cliff that threatens revenue from several key products. Executives said the company is rely…
- Dren Bio raises $350 million to advance rare blood cancer antibodyDren Bio, a California biotech, announced a $350 million financing round to fund late‑stage development and commercial preparation of its lead therapy, a CD94‑targeting monoclonal antibody known as…